Plain-English translation of NCT06325956 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether — a medication commonly used to treat polycystic ovary syndrome — works better in some people than others, depending on their immune system. Researchers will give you the medication for six months and take blood samples before and after treatment to measure changes in your immune cells. The goal is to understand if doctors can predict in advance who will benefit most from this treatment.
Polycystic ovary syndrome affects many women of childbearing age, but this medication doesn't work equally well for everyone. By studying your immune system, researchers hope to discover which patients are most likely to benefit from this treatment, so doctors can personalize care and help more people.
You will take tablets by mouth — starting at 1,000 mg per day for the first week, then 1,500 mg per day for the remaining five months. The research team will collect blood samples from you before you start the medication and again after the six-month treatment period to analyze your immune cells. You'll need to return for these blood draws and possibly follow-up visits to monitor how you're doing.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China
Shanghai 10th People's Hospital
Enrollment target
~100 participants
Started
March 2024
Primary completion
December 2025
Age range
18 Years – 45 Years
Sex
Female only
Last updated on clinicaltrials.gov in March 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Manna Zhang, doctor
Shanghai 10th People's Hospital